Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. on October 13, 2021. The report details the entry into a material definitive agreement to establish an "at-the-market" equity offering program.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the commission structure for the new sales agreement, set at 3.0% of gross proceeds from share sales.
Material Changes
On October 13, 2021, the company entered into a Sales Agreement with SVB Leerink LLC. This agreement authorizes the company to sell shares of its common stock from time to time through an "at-the-market" offering program. SVB Leerink will act as the agent for these sales. The company retains the discretion to set parameters for sales, including maximum share amounts, time periods, daily limits, and minimum prices. The agreement may be terminated by either party with five days' prior notice.
Guidance, Outlook, and Risks
The company has no obligation to sell any shares under the Sales Agreement and may suspend offers at its sole discretion. Shares will be issued pursuant to a shelf registration statement on Form S-3 (File No. 333-254862), originally filed in March 2021. The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the total number of shares authorized for sale under the Form S-3 shelf registration statement (File No. 333-254862).
- Monitor future filings for actual share sales executed under the SVB Leerink Sales Agreement.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific covenants and termination clauses.
- Check subsequent 10-Q or 10-K filings for the impact of this equity program on cash flow and share count.